On April 17, the Department of Bioinformatics at Korea University Sejong Campus held the ‘Spring 2025 Bioinformatics Seminar.’

 

The seminar featured Yoon Jungwon, CEO of Celltrion, as the guest speaker, and was attended by over 50 participants, including Professors Baek Seungpil and Kim Suji, Research Professor Min Kiha, as well as undergraduate and graduate students from the department.

 

Participants explored recent trends and innovation strategies in the global pharmaceutical industry and Korea’s burgeoning bioindustry, with a focus on ongoing research and development within the sector. Yoon provided an overview of the pharmaceutical market, emphasizing the central roles of chemical and antibody-based medicine. He also highlighted the increasing research activity in emerging modalities such as cell and gene therapies, antibody-drug conjugates (ADCs), bispecific antibodies, digital therapeutics, and radiopharmaceuticals.

 

Yoon noted that Korea maintains a leading global position in the biosimilar sector, driven by companies such as Celltrion and Samsung Bioepis. He also emphasized that Samsung Biologics is strengthening its global competitiveness in the Contract Development and Manufacturing Organization (CDMO) industry.

 

The seminar was jointly hosted and organized by the Department of Bioinformatics and the Biological Clock-based Anti-Aging Convergence RLRC(Regional-Leading Research Center; BCA2-RLRC).

 

 

KU Sejong Student PR Team, KUS-ON

Translator: Chang Jeoungeun